Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omeprazole for Fat Absorption in CF and EPI
NCT03551691Phase 2Completed
- Sponsor
- Children's Hospital of Philadelphia
- Start
- Aug 2018
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of omeprazole in exocrine pancreatic insufficiency (EPI) (2 arms), sponsored by Children's Hospital of Philadelphia. Primary endpoint: Coefficient of Fat Absorption at 28 days. Started Aug 2018; status: completed.
02
Drugs
omeprazole
03
Conditions
exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on NCT03551691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03551691.